BMY Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	14.08M
Vidutinė apimtis	15.91M
Rinkos kapitalizacija	88.58B
EPS	$0 ( 2024-04-25 )
Kita pelno data	( $1.680 ) 2024-07-25
Last Dividend	$0.600 ( 2024-01-04 )
Next Dividend	$0 ( N/A )
P/E	-14.10
ATR14	$0.0340 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Shanahan Karin	Sell	3 306	Restricted Stock Units
2024-04-01	Shanahan Karin	Buy	3 306	Common Stock, $0.10 par value
2024-04-01	Shanahan Karin	Sell	1 196	Common Stock, $0.10 par value
2024-03-31	Yale Phyllis R	Buy	645	Deferred Share Units
2024-03-31	Storch Gerald L	Buy	691	Deferred Share Units

INSIDER POWER
31.44
Last 100 transactions
Buy: 432 337 \| Sell: 225 479

Tūris Koreliacija

Ilgas: -0.60 (weak negative)

Trumpas: -0.82 (strong negative)

Signal:(48.576) Neutral

Bristol-Myers Squibb Co Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
UVV	0.926
AJAX	0.919
PYN	0.908
BSM	0.897
HLGN	0.892
BAK	0.89
HKIB	0.888
STZ	0.888
SDCI	0.886
WE	0.884

10 Labiausiai neigiamai susiję koreliacijos
IRL	-0.903
PANA	-0.883
IVH	-0.878
GOGN	-0.878
GOTU	-0.872
MGU	-0.871
ESM-UN	-0.871
STAR-PI	-0.869
HWKZ	-0.868
SGU	-0.866

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Bristol-Myers Squibb Co Koreliacija - Valiuta/Žaliavos

0.87
( strong )

0.88
( strong )

0.00
( neutral )

0.84
( strong )

-0.84
( strong negative )

-0.57
( weak negative )

Bristol-Myers Squibb Co Finansinės ataskaitos

Annual	2023
Pajamos:	$45.01B
Bruto pelnas:	$34.31B (76.24 %)
EPS:	$3.88

FY	2023
Pajamos:	$45.01B
Bruto pelnas:	$34.31B (76.24 %)
EPS:	$3.88

FY	2022
Pajamos:	$46.16B
Bruto pelnas:	$36.02B (78.04 %)
EPS:	$2.97

FY	2021
Pajamos:	$46.39B
Bruto pelnas:	$36.45B (78.57 %)
EPS:	$3.25

Financial Reports:

No articles found.

Bristol-Myers Squibb Co Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.540 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.570 (N/A)	$0.600 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bristol-Myers Squibb Co Dividend Information - Dividend Knight

Dividend Sustainability Score: 5.65 - average (55.60%) | Divividend Growth Potential Score: 2.75 - Decrease likely (45.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.00892	1972-07-26
Last Dividend	$0.600	2024-01-04
Next Dividend	$0	N/A
Payout Date	2024-02-01
Next Payout Date	N/A
# dividends	206	--
Total Paid Out	$44.07	--
Avg. Dividend % Per Year	2.48%	--
Score	4.75	--
Div. Sustainability Score	5.65
Div.Growth Potential Score	2.75
Div. Directional Score	4.20	--

Next Divdend (Est)
(2024-08-12)

$0.605 Estimate 60.24 %

Dividend Stability

0.96 Excellent

Dividend Score

4.75

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1972	$0.0178	0.95%
1973	$0.0482	2.36%
1974	$0.0452	3.25%
1975	$0.0491	3.23%
1976	$0.0536	2.60%
1977	$0.0655	3.24%
1978	$0.0725	3.64%
1979	$0.0856	4.04%
1980	$0.0714	3.31%
1981	$0.106	3.50%
1982	$0.121	3.85%
1983	$0.174	4.36%
1984	$0.190	3.71%
1985	$0.224	3.67%
1986	$0.214	2.74%
1987	$0.250	2.49%
1988	$0.519	5.04%
1989	$0.483	4.57%
1990	$0.521	3.84%
1991	$0.593	3.74%
1992	$0.492	2.34%
1993	$0.685	4.34%
1994	$0.871	6.37%
1995	$0.528	3.80%
1996	$0.893	4.38%
1997	$0.728	2.86%
1998	$0.557	1.24%
1999	$0.820	1.32%
2000	$0.932	1.52%
2001	$1.061	1.56%
2002	$1.400	2.75%
2003	$1.120	4.66%
2004	$0.840	2.86%
2005	$1.120	4.40%
2006	$1.120	4.82%
2007	$1.120	4.25%
2008	$1.550	5.93%
2009	$1.250	5.23%
2010	$0.960	3.75%
2011	$1.320	4.97%
2012	$1.360	3.88%
2013	$1.760	5.38%
2014	$1.450	2.77%
2015	$1.490	2.50%
2016	$1.140	1.70%
2017	$1.560	2.62%
2018	$1.600	2.61%
2019	$1.640	3.13%
2020	$2.29	3.62%
2021	$1.470	2.39%
2022	$2.16	3.49%
2023	$2.28	3.16%
2024	$0.600	1.14%

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
VGI	Dividend Royal	2024-02-09	Monthly	13	7.36%	8.50
KIO	Dividend Royal	2023-12-14	Monthly	12	7.05%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
ZTR	Dividend Royal	2024-02-09	Monthly	37	8.35%	8.50
PVL	Dividend King	2023-11-15	Monthly	14	9.37%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
NCV	Dividend Royal	2024-02-09	Monthly	22	7.68%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.135	1.500	-2.70	-4.05	[0 - 0.5]
returnOnAssetsTTM	-0.0621	1.200	-2.07	-2.48	[0 - 0.3]
returnOnEquityTTM	-0.230	1.500	-3.67	-5.50	[0.1 - 1]
payoutRatioTTM	-0.774	-1.000	-7.74	7.74	[0 - 1]
currentRatioTTM	1.110	0.800	9.45	7.56	[1 - 3]
quickRatioTTM	0.919	0.800	9.30	7.44	[0.8 - 2.5]
cashRatioTTM	0.361	1.500	9.10	10.00	[0.2 - 2]
debtRatioTTM	0.580	-1.500	0.338	-0.507	[0 - 0.6]
interestCoverageTTM	10.69	1.000	7.15	7.15	[3 - 30]
operatingCashFlowPerShareTTM	6.78	2.00	7.74	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.18	2.00	6.91	10.00	[0 - 20]
debtEquityRatioTTM	3.48	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.757	1.000	0.715	0.715	[0.2 - 0.8]
operatingProfitMarginTTM	0.306	1.000	5.88	5.88	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.239	1.000	9.78	9.78	[0.2 - 2]
assetTurnoverTTM	0.460	0.800	-0.268	-0.214	[0.5 - 2]
Total Score				5.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-14.55	1.000	-1.570	0	[1 - 100]
returnOnEquityTTM	-0.230	2.50	-2.36	-5.50	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.18	2.00	7.94	10.00	[0 - 30]
dividendYielPercentageTTM	5.29	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.78	2.00	7.74	10.00	[0 - 30]
payoutRatioTTM	-0.774	1.500	-7.74	7.74	[0 - 1]
pegRatioTTM	0.733	1.500	8.44	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.301	1.000	4.96	0	[0.1 - 0.5]
Total Score				2.75

Bristol-Myers Squibb Co

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.